Literature DB >> 2787831

Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.

T Aoki1, H Kikuchi, S Miyatake, Y Oda, K Iwasaki, T Yamasaki, T Kinashi, T Honjo.   

Abstract

IL-5 expresses various biologic effects on several types of lymphocytes, including B cells, eosinophils, and T cells. We demonstrated that the incubation of resting splenocytes from C57BL/6 mice in murine rIL-5 enhances IL-2-mediated lymphokine-activated killer (LAK) activity against various tumor cells. IL-5 alone, however, does not induce killer activity. IL-2-mediated LAK activity increases in proportion to the dose of IL-5. During the late phase of the culture period, IL-5 seems to have some effect on the induction of IL-2-mediated LAK activity. We expect that IL-5 will prove useful for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787831      PMCID: PMC2189403          DOI: 10.1084/jem.170.2.583

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Generation of cytotoxic T lymphocytes from thymocyte precursors to trinitrophenyl-modified self antigens. I. Requirement of both killer-helper factor(s) and interleukin 2 for CTL generation from a subpopulation of thymocytes.

Authors:  K Takatsu; Y Kikuchi; T Kanatani; K Okuno; T Hamaoka; A Tominaga; Y Sano
Journal:  J Immunol       Date:  1986-02-15       Impact factor: 5.422

2.  Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.

Authors:  K Itoh; A B Tilden; K Kumagai; C M Balch
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

3.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Authors:  M T Lotze; E A Grimm; A Mazumder; J L Strausser; S A Rosenberg
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

4.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

5.  Purification and physicochemical characterization of murine T cell replacing factor (TRF).

Authors:  K Takatsu; N Harada; Y Hara; Y Takahama; G Yamada; K Dobashi; T Hamaoka
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

6.  Antigen-induced T cell-replacing factor (TRF). I. Functional characterization of a TRF-producing helper T cell subset and genetic studies on TRF production.

Authors:  K Takatsu; A Tominaga; T Hamaoka
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

7.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors.

Authors:  H Karasuyama; F Melchers
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

8.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

9.  Production of a B cell growth-promoting activity, (DL)BCGF, from a cloned T cell line and its assay on the BCL1 B cell tumor.

Authors:  S L Swain; R W Dutton
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  9 in total

1.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Tryptophan-induced eosinophilia-myalgia syndrome.

Authors:  L A Criswell; K E Sack
Journal:  West J Med       Date:  1990-09

3.  Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.

Authors:  H G Klingemann; E Wong
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 4.  HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis.

Authors:  Rabia Nawaz; Sadia Zahid; Muhammad Idrees; Shazia Rafique; Muhammad Shahid; Ammara Ahad; Iram Amin; Iqra Almas; Samia Afzal
Journal:  Inflamm Res       Date:  2017-03-11       Impact factor: 4.575

5.  Interleukin-5 induces tumor suppression by peritoneal exudate cells in mice.

Authors:  Y Nakashima; S Mita; K Takatsu; M Ogawa
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

6.  Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.

Authors:  Y Masuda; S Mita; K Sakamoto; T Ishiko; M Ogawa
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

7.  Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes.

Authors:  C N Baxevanis; M L Tsiatas; N T Cacoullos; G Spanakos; C Liacos; I Missitzis; S I Papadhimitriou; M Papamichail
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.

Authors:  M R Alderson; H M Sassenfeld; M B Widmer
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

9.  Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression.

Authors:  K A Saraya; F R Balkwill
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.